Lactoferrin as Immune-Enhancement Strategy for SARS-CoV-2 Infection in Alzheimer's Disease Patients
| Autor: | Fernando Bartolomé, Luigi Rosa, Piera Valenti, Francisco Lopera, Jesús Hernández-Gallego, José Luis Cantero, Gorka Orive, Eva Carro |
|---|---|
| Přispěvatelé: | Instituto de Salud Carlos III, Unión Europea. Fondo Europeo de Desarrollo Regional (FEDER/ERDF), Comunidad de Madrid (España), Ministerio de Economía y Competitividad (España), Regional Government of Andalusia (España) |
| Rok vydání: | 2022 |
| Předmět: |
salivary lactoferrin
brain-immunity interactions brain efficacy Immunology Anti-Inflammatory Agents anti-inflammatory agents antimicrobial peptides Alzheimer Disease alzheimer disease Immunology and Allergy Animals Humans brain-immunity interaction iron disorders Brain-immunity interactions humans Saliva innate immunity Aged Inflammation saliva SARS-CoV-2 COVID-19 alzheimer’s disease inflammatory response Alzheimer's disease COVID-19 Drug Treatment lactoferrin dementia inflammation SARS-CoV2 aged animals cattle RNA viral Lactoferrin host-defense RNA Dementia Cattle Alzheimer’s disease viral ferrous sulfate |
| Zdroj: | Repisalud Instituto de Salud Carlos III (ISCIII) Addi. Archivo Digital para la Docencia y la Investigación instname |
| Popis: | Coronavirus 2 (SARS-CoV2) (COVID-19) causes severe acute respiratory syndrome. Severe illness of COVID-19 largely occurs in older people and recent evidence indicates that demented patients have higher risk for COVID-19. Additionally, COVID-19 further enhances the vulnerability of older adults with cognitive damage. A balance between the immune and inflammatory response is necessary to control the infection. Thus, antimicrobial and anti-inflammatory drugs are hopeful therapeutic agents for the treatment of COVID-19. Accumulating evidence suggests that lactoferrin (Lf) is active against SARS-CoV-2, likely due to its potent antiviral and anti-inflammatory actions that ultimately improves immune system responses. Remarkably, salivary Lf levels are significantly reduced in different Alzheimer's disease (AD) stages, which may reflect AD-related immunological disturbances, leading to reduced defense mechanisms against viral pathogens and an increase of the COVID-19 susceptibility. Overall, there is an urgent necessity to protect AD patients against COVID-19, decreasing the risk of viral infections. In this context, we propose bovine Lf (bLf) as a promising preventive therapeutic tool to minimize COVID-19 risk in patients with dementia or AD. This study was supported by grants from Instituto de Salud Carlos III (FIS21/00679 to EC and JH-G and PI21/00183 to FB), FEDER, Comunidad de Madrid (S2017/BMD-3700; NEUROMETAB-CM to EC), and CIBERNED (CB07/502 to EC); Spanish Ministry of Economy and Competitiveness (PID2020-119978RB-I00 to JC), CIBERNED, the Research Program for a Long-Life Society (0551_PSL_6_E to JC), the Junta de Andalucía (PY20_00858 to J.L.C.), the Andalucía-FEDER Program (UPO-1380913 to JC). Sí |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|